Abstract
Heparan sulfate proteoglycans (HSPGs) play vital roles in every step of tumor progression allowing cancer cells to proliferate, escape from immune response, invade neighboring tissues, and metastasize to distal sites away from the primary site. Several cancers including breast, lung, brain, pancreatic, skin, and colorectal cancers show aberrant modulation of several key HS biosynthetic enzymes such as 3-O Sulfotransferase and 6-O Sulfotransferase, and also catabolic enzymes such as HSulf-1, HSulf-2 and heparanase. The resulting tumor specific HS fine structures assist cancer cells to breakdown ECM to spread, misregulate signaling pathways to facilitate their proliferation, promote angiogenesis to receive nutrients, and protect themselves against natural killer cells. This review focuses on the changes in the expression of HS biosynthetic and catabolic enzymes in several cancers, the resulting changes in HS fine structures, and the effects of these tumor specific HS signatures on promoting invasion, proliferation, and metastasis. It is possible to retard tumor progression by modulating the deregulated biosynthetic and catabolic pathways of HS chains through novel chemical biology approaches.
Keywords: Proteoglycan, cancer, heparanase, sulfotransferase, sulfatase, heparan sulfate
Current Chemical Biology
Title: Chemical Tumor Biology of Heparan Sulfate Proteoglycans
Volume: 4 Issue: 1
Author(s): Karthik Raman and Balagurunathan Kuberan
Affiliation:
Keywords: Proteoglycan, cancer, heparanase, sulfotransferase, sulfatase, heparan sulfate
Abstract: Heparan sulfate proteoglycans (HSPGs) play vital roles in every step of tumor progression allowing cancer cells to proliferate, escape from immune response, invade neighboring tissues, and metastasize to distal sites away from the primary site. Several cancers including breast, lung, brain, pancreatic, skin, and colorectal cancers show aberrant modulation of several key HS biosynthetic enzymes such as 3-O Sulfotransferase and 6-O Sulfotransferase, and also catabolic enzymes such as HSulf-1, HSulf-2 and heparanase. The resulting tumor specific HS fine structures assist cancer cells to breakdown ECM to spread, misregulate signaling pathways to facilitate their proliferation, promote angiogenesis to receive nutrients, and protect themselves against natural killer cells. This review focuses on the changes in the expression of HS biosynthetic and catabolic enzymes in several cancers, the resulting changes in HS fine structures, and the effects of these tumor specific HS signatures on promoting invasion, proliferation, and metastasis. It is possible to retard tumor progression by modulating the deregulated biosynthetic and catabolic pathways of HS chains through novel chemical biology approaches.
Export Options
About this article
Cite this article as:
Raman Karthik and Kuberan Balagurunathan, Chemical Tumor Biology of Heparan Sulfate Proteoglycans, Current Chemical Biology 2010; 4 (1) . https://dx.doi.org/10.2174/2212796811004010020
DOI https://dx.doi.org/10.2174/2212796811004010020 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blockade of Jagged/Notch Pathway Abrogates Transforming Growth Factor β2-Induced Epithelial-Mesenchymal Transition in Human Retinal Pigment Epithelium Cells
Current Molecular Medicine Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC
Current Molecular Medicine Anti-Cancer Activity of Curcumin on Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Different Methods for Cell Viability and Proliferation Assay: Essential Tools in Pharmaceutical Studies
Anti-Cancer Agents in Medicinal Chemistry Deciphering of The Effect of Chemotherapeutic Agents on Human Glutathione S-Transferase Enzyme and MCF-7 Cell Line
Protein & Peptide Letters Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers
Current Pharmaceutical Design The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Alternative Spliced Variants as Biomarkers of Colorectal Cancer
Current Drug Metabolism Anti-tumor Activity of Propofol: A Focus on MicroRNAs
Current Cancer Drug Targets Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect
Current Pharmaceutical Biotechnology